Maravai LifeSciences Q2 revenue beats estimates on strong TriLink demand

Maravai Lifesciences Holdings

06/08/2026 21:10

Overview
Life science reagents supplier's Q2 revenue rose 9% yr/yr, beating analyst expectations
Q2 adjusted EBITDA beat analyst expectations, driven by TriLink segment demand
Company raised full-year 2026 adjusted EBITDA guidance, maintained revenue outlook

Outlook
Maravai sees 2026 revenue between $205 mln and $215 mln
Company raises 2026 adjusted EBITDA guidance to $33 mln-$35 mln from $30 mln-$32 mln
Company expects continued demand for TriLink and Cygnus products to support growth

Result Drivers
TRILINK DEMAND - TriLink revenue rose 11.5% yr/yr, driven by higher demand for research-use raw materials and GMP consumables used in clinical trials
CYGNUS GROWTH - Cygnus revenue grew 2.8% yr/yr, supported by demand for Host Cell Protein and ELISA kits and strength in China due to distributor ordering timing
NEW FACILITY AND PRODUCT ADOPTION - Co cited opening of GMP enzyme manufacturing facility and strong uptake of ModTail product line as supporting business momentum

Company press release: ID:nBwDg4Vja

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$51.40 mln
$48.68 mln (8 Analysts)
Q2 Net Loss
 
$21.60 mln
 
Q2 Adjusted EBITDA
Beat
$8.70 mln
$3.05 mln (8 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc is $6.00, about 6.4% below its August 5 closing price of $6.41

Reuters Recommended Reads
Aug 5 - Alpha Teknova Q2 revenue beats estimates, raises revenue 2026 outlook
Aug 5 - McKesson raises annual profit forecast on strong growth in specialty drug business
Aug 4 - Waters lifts annual forecasts on strong lab-equipment and diagnostics demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)